comprehensive -WSS

comprehensive

author：knowledge 2025-09-06 02:04:54 - browse：668

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Gene therapy has helped boys walk. Can scientists keep it that way?

WSS

Gene therapy has helped boys walk. Can scientists keep it that way?

What would happen to your eyes if you looked at the solar eclipse?

Lecanemab for Alzheimer's is coming. Is the health system ready?

New research casts further doubt on a common procedure used with IVF

HCA discloses massive data breach affecting 11 million patients

Leqembi, other new Alzheimer’s drugs require better biomarkers

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Alkermes shareholders re

Living with Fabry disease, a condition that causes chronic pain

Guidelines to prevent youth baseball injuries need more muscle

Retired US general questions alleged Putin, Prigozhin meeting

Continuity nursing helped my family in our darkest PICU moments

3 hurdles to bringing medical devices to the U.S. market

Psychedelics group wrestles with new pharma identity

Palantir health business leans on meeting customers’ needs

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

entertainment

Lecanemab for Alzheimer's is coming. Is the health system ready?

#NeedHerScience: shining a light on gender disparities in medicine

Gene therapy has helped boys walk. Can scientists keep it that way?

Why ADHD is under

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

The science behind Janet Jackson's pregnancy at 49

focus

hotspot

entertainment

leisure time